Caricamento...

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence

Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, although an indirect inhibitory effect on tumor growth and, more recently, a complex activity on antitumor immune response has been described. From approval by the US Food and Drug Administration (FDA) in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ther Adv Urol
Autori principali: Rizzo, Mimma, Porta, Camillo
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2017
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896861/
https://ncbi.nlm.nih.gov/pubmed/29662544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287217713902
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !